Myelin basic protein
- Generic Name
- Myelin basic protein
- Drug Type
- Biotech
- Unique Ingredient Identifier
- SSA5AV2ZFK
INmune Bio Completes Enrollment in Phase 2 Alzheimer's Trial and Reports Positive NK-Cell Data in Prostate Cancer Study
• INmune Bio completed enrollment for its Phase 2 Alzheimer’s Disease trial (AD02) focused on early AD patients with elevated neuroinflammation biomarkers.
• Interim analysis of the AD02 trial's blinded data showed a highly significant correlation (p<0.001) between EMACC cognitive measure and CDR-SB, a standard endpoint for AD trials.
• INKmune™ demonstrated excellent safety and increased NK-Cell activity in the first dosing cohort of a Phase I/II trial for metastatic Castration-Resistant Prostate Cancer (mCRPC).
• A new INKmune™ formulation supports the highest trial dose with single bag administration and expansion of bioreactor capacity for scalable manufacturing.
OCTOPUS Trial Shows Progress in Evaluating Alpha-Lipoic Acid and Metformin for Progressive MS
• The OCTOPUS trial, a multi-arm study, is assessing R/S alpha-lipoic acid and metformin for progressive multiple sclerosis, aiming to enroll 375 participants in its first stage.
• As of March 2024, 189 participants have been randomized, with a majority diagnosed with secondary progressive MS and an average disease duration of 20.6 years.
• The OCTOPUS trial seeks to address the significant unmet need for effective treatments for progressive MS, where ocrelizumab is currently the only FDA-approved option.
Cyclarity Launches Human Trial for Atherosclerosis
Cyclarity Therapeutics has initiated its first human clinical trial for atherosclerosis, focusing on its primary candidate cyclodextrin drug, UDP-003, marking a significant step in longevity and aging research.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath